Thursday, February 06, 2020 11:17:11 AM
Recent CGEN News
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy • PR Newswire (US) • 03/11/2024 11:00:00 AM
- Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 • PR Newswire (US) • 03/06/2024 12:00:00 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/05/2024 09:06:21 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 12:00:24 PM
- Compugen Reports Fourth Quarter and Full Year 2023 Results • PR Newswire (US) • 03/05/2024 12:00:00 PM
- U.S. Futures Dip, Crude Oil Fluctuates • IH Market News • 03/05/2024 11:05:54 AM
- Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 • PR Newswire (US) • 02/26/2024 12:00:00 PM
- Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 12:00:08 PM
- Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer • PR Newswire (US) • 02/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 12:10:06 PM
- Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer • PR Newswire (US) • 01/08/2024 12:05:00 PM
- Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement • PR Newswire (US) • 01/08/2024 12:00:00 PM
- Strong Open For Biotech Following Exclusive Agreement Announcement • AllPennyStocks.com • 12/19/2023 02:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/19/2023 12:12:07 PM
- Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer • PR Newswire (US) • 12/19/2023 12:10:00 PM
- Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology • PR Newswire (US) • 12/19/2023 12:05:00 PM
- Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program • Business Wire • 12/19/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/07/2023 12:00:05 PM
- Compugen Reports Third Quarter 2023 Results • PR Newswire (US) • 11/07/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/06/2023 12:00:07 PM
- Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy • PR Newswire (US) • 11/06/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/03/2023 08:35:23 PM
- Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification • PR Newswire (US) • 11/03/2023 08:35:00 PM
- Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer • PR Newswire (US) • 10/31/2023 01:00:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM